Global Rapid Influenza Diagnostic Tests (RIDT) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In 2021, The acquisition of Luminex Corporation, a business involved in the development of diagnostic tools for infectious diseases, was announced by DiaSorin SpA. This acquisition aimed to increase the diagnostic goods available in the United States, including those for the diagnosis of influenza. This tactical choice helped the business grow its clientele and strengthen its position in the market.

• In May 2021 Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which is used to detect SARS-CoV-2, influenza A, and influenza B.

The Global Rapid Influenza Diagnostic Tests (RIDT) Market has been segmented by test type, molecular type, product type, and end-user, addressing the increasing demand for quick, accurate, and easy-to-administer tests to diagnose influenza infections.

By Test Type, RIDTs primarily focus on detecting either the Influenza A or B virus. These tests are essential for identifying flu infections in their early stages, allowing for immediate treatment decisions. The test types available include immunoassays that detect viral antigens from respiratory specimens. The ease and speed of these tests are crucial for healthcare settings, where rapid diagnosis can significantly reduce the time spent on patient evaluation and lead to quicker therapeutic interventions.

By Molecular Type, RIDTs are divided into molecular tests and antigen-based tests. Molecular tests, including reverse-transcription polymerase chain reaction (RT-PCR) tests, detect the genetic material of the virus. These tests are more sensitive and accurate than traditional antigen-based tests, making them highly preferred in clinical and hospital settings. While antigen-based tests remain popular due to their simplicity and speed, molecular tests are growing in demand due to their higher accuracy, which reduces the likelihood of false negatives or positives. The growing reliance on molecular diagnostics is driven by the demand for more precise results, especially during flu seasons or pandemics like COVID-19.

By Product Type, the RIDT market is segmented into test kits and instruments. Test kits are highly sought after in homecare and outpatient settings due to their convenience and ease of use. They typically include all the necessary components for testing, such as swabs and reagent solutions. Instruments, such as handheld devices or desktop analyzers, are more commonly used in clinical laboratories for more advanced or confirmatory testing. These instruments provide higher accuracy and can handle multiple tests simultaneously, catering to high-volume testing environments.

By End-Use, the RIDT market is categorized into hospitals, clinics, diagnostic laboratories, and homecare settings. Hospitals and clinics are the largest end-users due to the high volume of patients requiring rapid testing during flu seasons. Diagnostic laboratories play a significant role in conducting confirmatory tests and supporting the clinical decision-making process. Homecare settings are increasingly adopting RIDTs due to the growing consumer preference for at-home healthcare solutions. The convenience and accessibility of at-home tests have expanded the market’s reach beyond traditional healthcare facilities.

In conclusion, the Global RIDT Market is characterized by a broad range of product types and applications, with molecular diagnostics gaining momentum due to their accuracy and precision, while test kits and antigen-based tests continue to cater to faster and more accessible diagnosis needs in various healthcare environments.

Global Rapid Influenza Diagnostic Tests (RIDT) Segment Analysis

In this report, the Global Rapid Influenza Diagnostic Tests (RIDT) Market has been segmented by Test, Type, Molecular, Product Type, End-Use and Geography.

Global Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Test

The segmentation of the Global Rapid Influenza Diagnostic Tests (RIDT) Market by Test into Traditional Diagnostic Test, Molecular Diagnostic Tests, and Other Molecular Test.

Traditional Diagnostic Tests in RIDT primarily include antigen-based tests, such as immunoassays, which detect viral antigens present in respiratory samples. These tests are well-established, offering quick results, typically within 15-30 minutes. They are often used in clinics, outpatient settings, and emergency departments due to their convenience, speed, and ease of use. However, they tend to have lower sensitivity compared to molecular tests, which can result in higher rates of false negatives, especially in patients with low viral loads or outside the peak of the infection.

Molecular Diagnostic Tests are based on the detection of viral genetic material, offering greater accuracy and sensitivity than traditional antigen-based methods. Reverse-transcription polymerase chain reaction (RT-PCR) is the most commonly used molecular method in RIDTs, capable of identifying Influenza A and B viruses with higher specificity. These tests are especially valuable in clinical and hospital settings where precise diagnosis is crucial for patient management. While molecular tests take longer than traditional tests (typically a few hours), their higher accuracy, especially during flu seasons or when confirming results, makes them highly preferred for diagnosing influenza infections.

Other Molecular Tests include nucleic acid amplification tests (NAATs) and isothermal amplification tests, which also detect the influenza virus's genetic material but use different amplification methods from RT-PCR. NAATs, for example, provide faster results than traditional PCR tests and can be used in point-of-care settings. These tests are increasingly gaining traction for their ability to deliver molecular-level accuracy without the complexity and longer turnaround times typically associated with traditional molecular tests. The adoption of such tests is growing due to the demand for rapid, accurate diagnostics in both clinical settings and at-home testing environments.

This segmentation provides a comprehensive view of the options available in the RIDT market, with traditional tests being popular for their speed and ease, molecular diagnostics dominating where accuracy is critical, and newer molecular technologies advancing the market's potential for rapid and reliable flu diagnosis.

Global Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Type

The segmentation of the Global Rapid Influenza Diagnostic Tests (RIDT) Market by Type into Type A Flu, Type B Flu, and Type C Flu.

Type A Flu is the most common and prevalent strain of influenza, known to cause seasonal epidemics and is associated with more severe illness compared to other types. RIDTs targeting Type A flu are the most widely used, as these tests are critical during flu seasons to detect influenza outbreaks. Type A influenza can further be subdivided into various subtypes, such as H1N1 and H3N2, making its identification crucial for monitoring viral mutations and seasonal variations. RIDTs that detect Type A influenza are in high demand across healthcare settings like hospitals, clinics, and diagnostic labs, where rapid diagnosis can significantly impact patient care and containment strategies.

Type B Flu typically causes less severe illness than Type A but can still lead to significant outbreaks, particularly in children. Diagnostic tests for Type B flu are also a key part of the RIDT market, as timely detection helps in differentiating between Type A and Type B infections. Although less common than Type A, Type B influenza still represents a major public health concern, particularly during peak flu seasons. RIDTs for Type B flu are essential for confirming diagnosis and determining appropriate treatment, particularly in regions where both A and B strains circulate.

Type C Flu is less common and generally causes milder illness compared to Types A and B. While RIDTs for Type C flu are less widespread in comparison, they play an important role in specific diagnostic scenarios, especially when distinguishing flu-like symptoms from other viral infections. Type C infections are generally not associated with seasonal flu epidemics, but the development of RIDTs for this strain ensures that a full spectrum of influenza infections can be diagnosed accurately, which is crucial for epidemiological monitoring and understanding the full range of influenza virus activity.

This segmentation highlights the diverse range of diagnostic needs within the RIDT market, with Type A and Type B flu tests being more prominent due to their higher incidence, while Type C flu tests cater to more specialized diagnostic cases.

Global Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Molecular

The segmentation of the Global Rapid Influenza Diagnostic Tests (RIDT) Market by Molecular into PCR, INAAT- NASBAT, and TMABAS.

PCR (Polymerase Chain Reaction), INAAT-NASBAT (Isothermal Nucleic Acid Amplification Test - Nucleic Acid Sequence-Based Amplification Test), and TMABAS (Transcription Mediated Amplification-Based Amplification System). These molecular diagnostic methods are designed to offer higher accuracy and sensitivity in detecting influenza viruses, providing faster results compared to traditional testing methods.

PCR (Polymerase Chain Reaction) is one of the most commonly used molecular methods in RIDTs. PCR is known for its high sensitivity and specificity, enabling the detection of even small quantities of the influenza virus's genetic material in patient samples. It works by amplifying the viral DNA or RNA, making it easier to identify the presence of the virus. PCR tests are considered the gold standard in molecular diagnostics due to their ability to distinguish between different strains of influenza, including Type A and Type B. However, PCR tests typically require specialized laboratory equipment and are not as rapid as some other RIDTs.

INAAT-NASBAT (Isothermal Nucleic Acid Amplification Test - Nucleic Acid Sequence-Based Amplification Test) is an emerging molecular diagnostic technique that offers faster results than traditional PCR tests. This method amplifies nucleic acids at a constant temperature (isothermal), making it more suitable for point-of-care settings as it does not require complex thermal cycling equipment. INAAT-NASBAT tests can provide rapid, reliable results for influenza virus detection, with a quick turnaround time, typically within 30 minutes to an hour. This technology is particularly beneficial for use in settings like clinics and emergency rooms, where fast decision-making is crucial.

TMABAS (Transcription Mediated Amplification-Based Amplification System) is another molecular testing method used in the RIDT market, offering high sensitivity for detecting influenza viruses. TMABAS works by amplifying RNA sequences of the virus, specifically the influenza virus RNA. This method is particularly valued for its ability to detect both influenza A and B strains quickly and accurately, often without the need for specialized lab facilities. TMABAS is widely utilized in healthcare environments where quick diagnosis is necessary for immediate treatment decisions, such as in outpatient clinics and emergency care units.

This segmentation illustrates the growing use of molecular diagnostic technologies in the RIDT market, with PCR being the most widely recognized method, and INAAT-NASBAT and TMABAS providing more rapid alternatives that are gaining traction in point-of-care settings.

Global Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Geography

In this report, the Global Rapid Influenza Diagnostic Tests (RIDT) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Rapid Influenza Diagnostic Tests (RIDT) Market Share (%), by Geographical Region, 2024

The Global Rapid Influenza Diagnostic Tests (RIDT) Market exhibits varying shares across different geographical regions, reflecting the diverse healthcare landscapes, influenza prevalence rates, and adoption of rapid diagnostic technologies. North America commands a significant market share in the RIDT market, driven by robust healthcare infrastructure, high awareness about influenza diagnostics, and proactive public health measures. The United States contributes significantly to this share, with a strong presence of key market players, stringent regulatory frameworks, and advanced healthcare facilities adopting rapid influenza testing solutions. Additionally, the region's emphasis on early diagnosis, prompt treatment, and influenza surveillance programs further fuels the demand for RIDTs, positioning North America as a key market leader in rapid influenza diagnostics.

Europe holds a considerable share in the Global RIDT Market, characterized by a well-established healthcare system, high influenza vaccination rates, and proactive disease management strategies. Countries such as Germany, France, and the United Kingdom drive market growth, supported by government initiatives, public health campaigns, and increasing adoption of point-of-care testing solutions. Europe's market share is also influenced by the prevalence of seasonal influenza outbreaks, stringent regulatory standards for diagnostic devices, and collaborations between healthcare providers and diagnostic manufacturers to improve influenza detection and management.

The Asia-Pacific region emerges as a rapidly growing market for Rapid Influenza Diagnostic Tests (RIDT), fueled by expanding healthcare infrastructure, rising influenza prevalence rates, and growing awareness about the importance of rapid diagnostics. Countries such as China, Japan, and India witness significant market growth, driven by government investments in healthcare, increasing demand for point-of-care testing in clinical settings, and advancements in influenza surveillance programs. The Asia-Pacific region's market share is characterized by the adoption of innovative RIDTs, development of multiplexed testing solutions, and integration with telemedicine platforms, contributing to improved influenza management and healthcare accessibility across the region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Rapid Influenza Diagnostic Tests (RIDT) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Rapid Influenza Diagnostic Tests (RIDT) Market include :

• Roche Diagnostics
• Abbott Laboratories
• Quidel Corporation
• Thermo Fisher Scientific
• BD (Becton, Dickinson and Company)
• DiaSorin
• Luminex Corporation
• Meridian Bioscience
• Cepheid
• Sekisui Diagnostics

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis